SAN MARINO, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Dr. M. Karen Newell, Ph.D., a lead scientist at biotechnology company Viral Genetics , will address the 11th Annual SoCalBio Investor and Partnership Conference. Dr. Newell’s presentation entitled: “The Impact of Custom Peptides on Chronic Inflammation,” will take place mid-morning on Thursday, September 17, 2009. The conference is being held at The Loews Santa Monica Beach Hotel in Santa Monica, California.
ABOUT VIRAL GENETICS:
Headquartered in San Marino, California, Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company has an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed by M. Karen Newell, Ph.D., that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to advance a technology developed by University of Colorado Professor M. Karen Newell called “metabolic disruption technology” (MDT), which focuses on blocking a tumor cell’s ability to generate energy from glucose or from fatty acids. Viral Genetics has an option to acquire exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado. Online at www.viralgenetics.com.
Contact: Haig Keledjian, 626-334-5310
SOURCE Viral Genetics
CONTACT: Haig Keledjian of Viral Genetics, +1-626-334-5310
Web site: http://www.viralgenetics.com/
Company News On-Call: http://www.prnewswire.com/comp/905553 .html
